In addition, because APS is associated with mTOR activation, further studies should focus on evaluating the role of the mTOR pathway in aPL-associated intrastent restenosis in HD patients and on assessing mTOR inhibitor-eluting balloons or stents. Here, MTOR is linked to autoimmune polyendocrinopathy.